Artificial Intelligence (AI) in Drug Discovery - Global Market Trajectory & Analytics

Description Table of
Contents

LOGIN TO ACCESS EXECUTIVE SUMMARY
PRINTER FRIENDLY

Global Artificial Intelligence (AI) in Drug Discovery Market to Reach $2.9 Billion by 2027

Amid the COVID-19 crisis, the global market for Artificial Intelligence (AI) in Drug Discovery estimated at US$589.5 Million in the year 2020, is projected to reach a revised size of US$2.9 Billion by 2027, growing at a CAGR of 25.7% over the analysis period 2020-2027. Oncology, one of the segments analyzed in the report, is projected to record a 22.4% CAGR and reach US$722.9 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Neurodegenerative Diseases segment is readjusted to a revised 23.6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $176.3 Million, While China is Forecast to Grow at 25.2% CAGR

The Artificial Intelligence (AI) in Drug Discovery market in the U.S. is estimated at US$176.3 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$511.4 Million by the year 2027 trailing a CAGR of 25.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 22.7% and 22.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 18.3% CAGR.

Metabolic Diseases Segment to Record 27.5% CAGR

In the global Metabolic Diseases segment, USA, Canada, Japan, China and Europe will drive the 27.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$87 Million in the year 2020 will reach a projected size of US$475.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$351.2 Million by the year 2027.

Select Competitors (Total 36 Featured):

Atomwise, Inc.
Benevolentai
Berg LLC
Bioage
Cloud Pharmaceuticals, Inc.
Cyclica
Deep Genomics
Envisagenics
Exscientia
Google (A Subsidiary of Alphabet Inc.)
IBM Corporation
Insilico Medicine
Microsoft Corporation
Numedii, Inc.
Numerate
NVIDIA Corporation
Owkin, Inc.
Twoxar, Incorporated
Verge Genomics
Xtalpi, Inc.

Note: Product cover images may vary from those shown

LOGIN TO ACCESS EXECUTIVE SUMMARY
PRINTER FRIENDLY

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Table 2: World 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
Table 3: World Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Table 4: World 7-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
Table 5: World Current & Future Analysis for Neurodegenerative Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Table 6: World 7-Year Perspective for Neurodegenerative Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
Table 7: World Current & Future Analysis for Metabolic Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Table 8: World 7-Year Perspective for Metabolic Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
Table 9: World Current & Future Analysis for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Table 10: World 7-Year Perspective for Cardiovascular Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
Table 11: World Current & Future Analysis for Infectious Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Table 12: World 7-Year Perspective for Infectious Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
Table 13: World Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Table 14: World 7-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
Table 15: World Current & Future Analysis for Drug Optimization & Repurposing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Table 16: World 7-Year Perspective for Drug Optimization & Repurposing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
Table 17: World Current & Future Analysis for Preclinical Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Table 18: World 7-Year Perspective for Preclinical Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
Table 19: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Table 20: World 7-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 21: USA Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 22: USA 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2020 & 2027
Table 23: USA Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 24: USA 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2020 & 2027
CANADA
Table 25: Canada Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 26: Canada 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2020 & 2027
Table 27: Canada Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 28: Canada 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2020 & 2027
JAPAN
Table 29: Japan Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 30: Japan 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2020 & 2027
Table 31: Japan Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 32: Japan 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2020 & 2027
CHINA
Table 33: China Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 34: China 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2020 & 2027
Table 35: China Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 36: China 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2020 & 2027
EUROPE
Table 37: Europe Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Table 38: Europe 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
Table 39: Europe Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 40: Europe 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2020 & 2027
Table 41: Europe Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 42: Europe 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2020 & 2027
FRANCE
Table 43: France Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 44: France 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2020 & 2027
Table 45: France Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 46: France 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2020 & 2027
GERMANY
Table 47: Germany Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 48: Germany 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2020 & 2027
Table 49: Germany Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 50: Germany 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2020 & 2027
ITALY
Table 51: Italy Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 52: Italy 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2020 & 2027
Table 53: Italy Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 54: Italy 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2020 & 2027
UNITED KINGDOM
Table 55: UK Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 56: UK 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2020 & 2027
Table 57: UK Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 58: UK 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2020 & 2027
REST OF EUROPE
Table 59: Rest of Europe Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 60: Rest of Europe 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2020 & 2027
Table 61: Rest of Europe Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 62: Rest of Europe 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2020 & 2027
ASIA-PACIFIC
Table 63: Asia-Pacific Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 64: Asia-Pacific 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2020 & 2027
Table 65: Asia-Pacific Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 66: Asia-Pacific 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2020 & 2027
REST OF WORLD
Table 67: Rest of World Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 68: Rest of World 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2020 & 2027
Table 69: Rest of World Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 70: Rest of World 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2020 & 2027

IV. COMPETITION

Total Companies Profiled: 36

Note: Product cover images may vary from those shown

RELATED TAGS

RELATED PRODUCTS

Artificial Intelligence (AI) in Drug Discovery Global Market Report 2020-30: COVID-19 Growth and Change

Artificial Intelligence (AI) in Drug Discovery Market by Component (Software, Service), Technology (ML, DL), Application (Neurodegenerative Diseases, Immuno-Oncology, CVD), End User (Pharmaceutical & Biotechnology, CRO), Region - Global forecast to 2024

Global Artificial Intelligence (AI) in Drug Discovery Market 2020-2026 by Offering, Technology, Drug Type, Therapeutic Area, Application, End User, and Region: Trend Forecast and Growth Opportunity

Artificial Intelligence in Drug Discovery Market Research Report by Offering, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19

AI in Drug Discovery Market by Component, Technology, by Application, by End User, by Geography - Global Opportunity Analysis and Industry Forecast up to 2026